Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease
Authors:
- 13 March 2010
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 25 (6) , 1139-1146
Abstract
Angiotensin converting enzyme (ACE) inhibition is a common therapeutic modality in the treatment of autosomal recessive polycystic kidney disease (ARPKD). This study was designed to investigate whether chronic inhibition of ACE would have a therapeutic effect in attenuating the progression of renal cystogenesis in an orthologous rat model of ARPKD, the polycystic kidney (PCK) rat. Lisinopril (3 mg/kg per day) was administered orally for a period of 12 weeks, beginning at post-natal week 4. Lisinopril treatment resulted in an ∼30% improvement in the collecting duct cystic indices (CT CI) of PCK animals. Activation of extracellular signal-regulated kinase 1 (ERK1) and 2 (ERK2), proliferative signaling markers, and proliferating cell nuclear antigen (PCNA), an end-point marker for proliferation, was reduced following chronic treatment with lisinopril compared to that in vehicle-treated PCK rats. To assess whether apoptotic pathways were altered due to chronic ACE inhibition, we examined p38 mitogen activated protein kinase (MAPK) and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), which are markers of apoptotic signaling cascades. p38 MAPK was significantly reduced (P < 0.0001) following chronic treatment with lisinopril, but no change in the activation of SAPK/JNK could be detected by immunoblot analysis. Lisinopril treatment resulted in a significant reduction (P < 0.01) in cleaved caspase-7 levels, but not caspase-3 activity, in PCK rat kidneys compared to the vehicle-treated PCK rat kidneys. Proteinuria was completely ameliorated in the presence of chronic ACE inhibition in the lisinopril-treated rats compared with the vehicle-treated PCK rats. In all, these findings demonstrated that chronic ACE inhibition can beneficially alter proliferative and apoptotic pathways to promote therapeutic reductions in renal cyst development in ARPKD.Keywords
This publication has 43 references indexed in Scilit:
- Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKDAmerican Journal of Physiology-Renal Physiology, 2009
- Caspase-3 Gene Deletion Prolongs Survival in Polycystic Kidney DiseaseJournal of the American Society of Nephrology, 2008
- Temporal Relationship between Renal Cyst Development, Hypertension and Cardiac Hypertrophy in a New Rat Model of Autosomal Recessive Polycystic Kidney DiseaseKidney and Blood Pressure Research, 2007
- Review: Novel roles of intracrine angiotensin II and signalling mechanisms in kidney cellsJournal of the Renin-Angiotensin-Aldosterone System, 2007
- Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD)Cell and tissue research, 2006
- Extracellular Signal–Regulated Kinase Inhibition Slows Disease Progression in Mice with Polycystic Kidney DiseaseJournal of the American Society of Nephrology, 2006
- Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (ADPKD)Kidney International, 2005
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney diseaseKidney International, 2002
- Diuretics versus Angiotensin-Converting Enzyme Inhibitors in Autosomal Dominant Polycystic Kidney DiseaseAmerican Journal of Nephrology, 2001